FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283376118> ?p ?o ?g. }

• W4283376118 endingPage "1617" @default.
• W4283376118 startingPage "1616" @default.
• W4283376118 abstract "Background: Pyruvate kinase (PK) deficiency is a rare, inherited, non-spherocytic hemolytic anemia associated with acute and long-term complications, as well as a spectrum of signs and symptoms including jaundice, fatigue, and dyspnea. PK deficiency has a profound wide-ranging impact on health-related quality of life (HRQoL). Mitapivat (AG-348), a first-in-class, oral, allosteric activator of PK, was shown to improve hemoglobin (Hb), hemolysis, and hematopoiesis in a global, phase 3, randomized, placebo (PBO)-controlled trial evaluating mitapivat efficacy and safety in adults with PK deficiency who were not regularly transfused (ACTIVATE; NCT03548220). Furthermore, significant improvements in patient-reported outcomes (PROs) (measured by disease-specific PRO instruments: the PK deficiency diary [PKDD] and the PK deficiency impact assessment [PKDIA]) were demonstrated in patients (pts) receiving mitapivat compared with PBO. The PKDD is a self-administered, 7-item daily diary to assess the signs and symptoms of PK deficiency (including jaundice, tiredness, and shortness of breath), while the PKDIA is a 12-item weekly measure assessing the impacts of PK deficiency (pts rated the frequency of occurrence or difficulty of various activities). Aims: To describe PKDD and PKDIA outcomes for the subset of pts in the ACTIVATE trial who achieved the primary endpoint of Hb response, defined as a ≥1.5 g/dL increase in Hb from baseline (BL), sustained at ≥2 scheduled assessments at weeks (wks) 16, 20, and 24. Methods: Eighty pts were randomized 1:1 to receive mitapivat (5/20/50 mg twice daily) or PBO for 24 wks in the ACTIVATE trial. Change from BL to wk 24 in PKDD and PKDIA scores were prespecified secondary endpoints. For this post hoc analysis, changes from BL in PKDD weekly mean scores and PKDIA scores measured at scheduled visits (wks 4, 8, 12, 16, 20, and 24) were summarized for Hb responders, the overall mitapivat treatment arm, and PBO, using mean and 95% confidence intervals (CIs). For both the PKDD and the PKDIA, a lower score represents a lower disease burden. Results: In the ACTIVATE trial, 16/40 (40%) pts receiving mitapivat met the primary endpoint of Hb response compared with none for PBO (0/40; 0%). At wk 24, mean (95% CI) change from BL in PKDD weekly mean score was ‒7.12 (‒10.98, ‒3.27) for pts who achieved Hb response, ‒5.43 (‒7.47, ‒3.40) for the overall mitapivat treatment arm, and ‒1.86 (–4.04, 0.32) for the PBO arm (Figure 1a). At wk 24, mean (95% CI) change from BL in PKDIA score was ‒8.07 (‒11.05, ‒5.08) for pts who achieved Hb response, ‒4.82 (‒7.18, ‒2.46) for the overall mitapivat treatment arm, and ‒1.06 (‒3.70, 1.59) for the PBO arm (Figure 1b). Across both PRO instruments, improvements among mitapivat pts who achieved Hb response were sustained over time. Image:Summary/Conclusion: In the ACTIVATE trial, mitapivat-treated pts demonstrated significant improvements in signs, symptoms, and impacts based on PK deficiency-specific PRO instruments, compared with PBO. This analysis further reveals that improvements were greater in the subset of mitapivat-treated pts who achieved the primary endpoint. Together, these data indicate that mitapivat has the potential to improve HRQoL in pts with PK deficiency who are not regularly transfused." @default.
• W4283376118 created "2022-06-25" @default.
• W4283376118 creator A5007020077 @default.
• W4283376118 creator A5018102572 @default.
• W4283376118 creator A5023313638 @default.
• W4283376118 creator A5027937488 @default.
• W4283376118 creator A5057628253 @default.
• W4283376118 creator A5059252057 @default.
• W4283376118 creator A5064622256 @default.
• W4283376118 creator A5066258828 @default.
• W4283376118 creator A5078550841 @default.
• W4283376118 creator A5084406853 @default.
• W4283376118 creator A5086391077 @default.
• W4283376118 date "2022-06-01" @default.
• W4283376118 modified "2023-10-01" @default.
• W4283376118 title "P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL" @default.
• W4283376118 doi "https://doi.org/10.1097/01.hs9.0000849796.83034.ba" @default.
• W4283376118 hasPublicationYear "2022" @default.
• W4283376118 type Work @default.
• W4283376118 citedByCount "0" @default.
• W4283376118 crossrefType "journal-article" @default.
• W4283376118 hasAuthorship W4283376118A5007020077 @default.
• W4283376118 hasAuthorship W4283376118A5018102572 @default.
• W4283376118 hasAuthorship W4283376118A5023313638 @default.
• W4283376118 hasAuthorship W4283376118A5027937488 @default.
• W4283376118 hasAuthorship W4283376118A5057628253 @default.
• W4283376118 hasAuthorship W4283376118A5059252057 @default.
• W4283376118 hasAuthorship W4283376118A5064622256 @default.
• W4283376118 hasAuthorship W4283376118A5066258828 @default.
• W4283376118 hasAuthorship W4283376118A5078550841 @default.
• W4283376118 hasAuthorship W4283376118A5084406853 @default.
• W4283376118 hasAuthorship W4283376118A5086391077 @default.
• W4283376118 hasBestOaLocation W42833761181 @default.
• W4283376118 hasConcept C126322002 @default.
• W4283376118 hasConcept C142724271 @default.
• W4283376118 hasConcept C159110408 @default.
• W4283376118 hasConcept C168563851 @default.
• W4283376118 hasConcept C187212893 @default.
• W4283376118 hasConcept C20251656 @default.
• W4283376118 hasConcept C203092338 @default.
• W4283376118 hasConcept C204787440 @default.
• W4283376118 hasConcept C27081682 @default.
• W4283376118 hasConcept C2778248108 @default.
• W4283376118 hasConcept C2778456037 @default.
• W4283376118 hasConcept C2779902561 @default.
• W4283376118 hasConcept C2779951463 @default.
• W4283376118 hasConcept C2780644154 @default.
• W4283376118 hasConcept C2780854706 @default.
• W4283376118 hasConcept C62231903 @default.
• W4283376118 hasConcept C71924100 @default.
• W4283376118 hasConcept C90924648 @default.
• W4283376118 hasConceptScore W4283376118C126322002 @default.
• W4283376118 hasConceptScore W4283376118C142724271 @default.
• W4283376118 hasConceptScore W4283376118C159110408 @default.
• W4283376118 hasConceptScore W4283376118C168563851 @default.
• W4283376118 hasConceptScore W4283376118C187212893 @default.
• W4283376118 hasConceptScore W4283376118C20251656 @default.
• W4283376118 hasConceptScore W4283376118C203092338 @default.
• W4283376118 hasConceptScore W4283376118C204787440 @default.
• W4283376118 hasConceptScore W4283376118C27081682 @default.
• W4283376118 hasConceptScore W4283376118C2778248108 @default.
• W4283376118 hasConceptScore W4283376118C2778456037 @default.
• W4283376118 hasConceptScore W4283376118C2779902561 @default.
• W4283376118 hasConceptScore W4283376118C2779951463 @default.
• W4283376118 hasConceptScore W4283376118C2780644154 @default.
• W4283376118 hasConceptScore W4283376118C2780854706 @default.
• W4283376118 hasConceptScore W4283376118C62231903 @default.
• W4283376118 hasConceptScore W4283376118C71924100 @default.
• W4283376118 hasConceptScore W4283376118C90924648 @default.
• W4283376118 hasLocation W42833761181 @default.
• W4283376118 hasLocation W42833761182 @default.
• W4283376118 hasLocation W42833761183 @default.
• W4283376118 hasLocation W42833761184 @default.
• W4283376118 hasOpenAccess W4283376118 @default.
• W4283376118 hasPrimaryLocation W42833761181 @default.
• W4283376118 hasRelatedWork W2061302546 @default.
• W4283376118 hasRelatedWork W2093972784 @default.
• W4283376118 hasRelatedWork W2294682668 @default.
• W4283376118 hasRelatedWork W2323171152 @default.
• W4283376118 hasRelatedWork W2328388422 @default.
• W4283376118 hasRelatedWork W2412859794 @default.
• W4283376118 hasRelatedWork W2414213587 @default.
• W4283376118 hasRelatedWork W2890159182 @default.
• W4283376118 hasRelatedWork W2969236193 @default.
• W4283376118 hasRelatedWork W4381855782 @default.
• W4283376118 hasVolume "6" @default.
• W4283376118 isParatext "false" @default.
• W4283376118 isRetracted "false" @default.
• W4283376118 workType "article" @default.